BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. More Details
Flawless balance sheet and fair value.
Share Price & News
How has BioSyent's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RX is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: RX's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: RX underperformed the Canadian Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: RX exceeded the Canadian Market which returned -0.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is BioSyent's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHow Much Did BioSyent's(CVE:RX) Shareholders Earn From Share Price Movements Over The Last Three Years?
4 weeks ago | Simply Wall StHow Is BioSyent's (CVE:RX) CEO Compensated?
1 month ago | Simply Wall StWe Think BioSyent's (CVE:RX) Statutory Profit Might Understate Its Earnings Potential
Is BioSyent undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RX (CA$7.05) is trading below our estimate of fair value (CA$9.47)
Significantly Below Fair Value: RX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RX is good value based on its PE Ratio (19.4x) compared to the CA Pharmaceuticals industry average (23x).
PE vs Market: RX is poor value based on its PE Ratio (19.4x) compared to the Canadian market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RX is overvalued based on its PB Ratio (3.6x) compared to the CA Pharmaceuticals industry average (1.5x).
How is BioSyent forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RX's forecast earnings growth is above the savings rate (1.7%).
Earnings vs Market: Insufficient data to determine if RX's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RX's revenue (14.5% per year) is forecast to grow faster than the Canadian market (6.1% per year).
High Growth Revenue: RX's revenue (14.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RX's Return on Equity is forecast to be high in 3 years time
How has BioSyent performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RX has high quality earnings.
Growing Profit Margin: RX's current net profit margins (21.5%) are lower than last year (22.2%).
Past Earnings Growth Analysis
Earnings Trend: RX's earnings have grown by 6.1% per year over the past 5 years.
Accelerating Growth: RX's earnings growth over the past year (5.6%) is below its 5-year average (6.1% per year).
Earnings vs Industry: RX earnings growth over the past year (5.6%) exceeded the Pharmaceuticals industry -45%.
Return on Equity
High ROE: RX's Return on Equity (19.4%) is considered low.
How is BioSyent's financial position?
Financial Position Analysis
Short Term Liabilities: RX's short term assets (CA$26.6M) exceed its short term liabilities (CA$3.7M).
Long Term Liabilities: RX's short term assets (CA$26.6M) exceed its long term liabilities (CA$1.7M).
Debt to Equity History and Analysis
Debt Level: RX is debt free.
Reducing Debt: RX had no debt 5 years ago.
Debt Coverage: RX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RX has no debt, therefore coverage of interest payments is not a concern.
What is BioSyent current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RX's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. René C. Goehrum has been the Chairman of BioSyent Inc. since June 1999 and its Chief Executive Officer since May 1999 and also its President since June 2006. Mr. Goehrum served as the President and ser...
CEO Compensation Analysis
Compensation vs Market: René's total compensation ($USD381.72K) is above average for companies of similar size in the Canadian market ($USD166.12K).
Compensation vs Earnings: René's compensation has been consistent with company performance over the past year.
|VP of Finance & CFO||2.17yrs||CA$260.94k||0.22% |
|Vice President of Corporate Development||2.17yrs||CA$244.11k||0.23% |
|Director of Human Resources||1.83yrs||no data||0.067% |
Experienced Management: RX's management team is considered experienced (2.2 years average tenure).
|Independent Director||2.5yrs||CA$29.90k||0.80% |
|Lead Independent Director||2.83yrs||CA$29.90k||1.28% |
|Independent Director||2.83yrs||CA$27.60k||0.080% |
|Independent Director||2.83yrs||CA$27.60k||0.11% |
|Independent Director||6.83yrs||CA$27.60k||0.011% |
Experienced Board: RX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BioSyent Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BioSyent Inc.
- Ticker: RX
- Exchange: TSXV
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$91.581m
- Shares outstanding: 12.81m
- Website: https://www.biosyent.com
- BioSyent Inc.
- 2476 Argentia Road
- Suite 402
- L5N 6M1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RX||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Sep 1988|
|BIOY.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Sep 1988|
BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/27 00:21|
|End of Day Share Price||2020/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.